GILENYA

GILENYA (fingolimod HCL) is an oral small-molecule sphingosine 1-phosphate receptor modulator approved in 2010 for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug's active metabolite, fingolimod-phosphate, binds with high affinity to S1P receptors 1, 3, 4, and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral lymphocyte counts. While the exact mechanism in MS remains incompletely understood, the therapeutic effect likely involves reduced lymphocyte migration into the central nervous system. GILENYA established itself as a foundational oral DMT (disease-modifying therapy) in the MS market and remains in peak commercial lifecycle despite growing competition from newer agents.